In the News: Health Care Heroes Award

ivWatch Chief Medical Officer, Dr. Brian Clare, was named a 2019 Health Care Hero for the ‘Innovations in Health Care’ category. Read more on this special report by Inside Business here.

In the News: “Best of Sensors Expo” Award Finalists

sensors

Sensors Online Announces ivWatch as a “Best of Sensors Expo” Award Finalist

Sensors Expo & Conference, the nation’s leading event focused exclusively on sensors and sensor-integrated systems, in conjunction with Sensors Online, announced ivWatch as a finalist of the 2018 Best of Sensors Expo Awards in the “Application” category. The competition highlights the advances in both innovations and real-world applications of sensors. ivWatch is one of eight companies in the running for the application award which is designed to recognize sensor use in the wider world that are distinctive and have the potential to change the way people work or serve a real industry need. Read more here.

ivWatch Awarded Breakthrough Technology Agreement with Premier

HAMPTON, Va.., February 6, 2018 – ivWatch, LLC has been awarded a group purchasing agreement as a Breakthrough Technology with Premier. Effective Feb.1, the new agreement allows Premier members, at their discretion, to take advantage of special pricing and terms pre-negotiated by Premier for the ivWatch Model 400, a continuous monitoring device for the early detection of peripheral IV (PIV) infiltrations.

“We are thrilled to be recognized by Premier as a Breakthrough Technology which accelerates the standard GPO process and enables us to educate more organizations about our technology offering a new standard of care for PIVs,” said Scott Hensley, vice president of sales and business development at ivWatch. “This recognition is a testament to the need for a technology solution in hospitals for continuous IV monitoring for early detection of IV infiltrations and extravasations.”

This relationship enables Premier members to implement continuous monitoring of a patient’s PIV for evidence of infiltrations to improve patient outcomes. Intravenous therapy is a routine part of treatment for nearly 80 percent of patients in the U.S., yet more than 20 percent of these IVs may fail due to infiltration, risking both a serious drug delivery error and tissue damage. The ivWatch sensor technology is a solution to aid the clinician in early detection of this most serious event.

Premier is a leading healthcare improvement company, uniting an alliance of approximately 3,900 U.S. hospitals and 150,000 other providers to transform healthcare. With integrated data and analytics, collaboratives, supply chain solutions, and advisory and other services, Premier enables better care and outcomes at a lower cost.

About ivWatch:
ivWatch, LLC is the leading medical device manufacturer and biosensor technology company focused on improving patient safety and the effectiveness of intravenous therapy. Our dedicated and passionate team is focused on our company vision of eliminating patient harm caused by infiltrations and extravasations. Through our innovative monitored IV solutions, we help minimize the risks associated with adverse IV events. Follow us on Twitter @ivWatch or Facebook @ivWatchLLChttps://www.ivwatch.com/

ivWatch Awarded New Innovative Technology Contract from Vizient, Inc.

HAMPTON, Va., August 29, 2017– ivWatch, LLC, the leading provider of continuous monitoring devices for the early detection of peripheral IV infiltrations, announced it has been awarded an Innovative Technology contract from Vizient, Inc. the largest member-driven health care performance improvement company in the country.

The Innovative Technology contract was awarded to ivWatch based on recommendations for the ivWatch Model 400 device by providers with expertise in this category who serve on one of Vizient’s member-led councils. Innovative Technology contracts are reserved for technologies that demonstrate an ability to enhance clinical care or patient safety, and those that improve an organization’s care delivery and business model.

The ivWatch Model 400 continuously monitors a patient’s peripheral IV for evidence of infiltrations, which occur when medication or fluid leaks into the surrounding tissue. Intravenous therapy is a routine part of treatment for nearly 80 percent of patients in the U.S., yet more than 20 percent of these IVs may fail because of infiltration, risking both a serious drug delivery error and tissue damage. Earlier detection of those failures, via ivWatch sensor technology, is the new and next step in minimizing this potential for injury.

“The Innovative Technology contract gives Vizient’s diverse membership a simple and more affordable means for adopting continuous IV monitoring and validates the excitement we’ve seen in hospitals across the country about our unique technology,” said Gary Warren, president and CEO of ivWatch, LLC. “IV infiltration is a major problem that can lead to serious medical complications and even amputation. This contract with Vizient is one more step towards our vision of eliminating the harm associated with IV infiltrations.”

“Due to the number of products and services being released and marketed as ‘innovative,’ member hospitals truly value the thorough innovative technology review process in place at Vizient to help them identify products worth further evaluation at their own facilities,” said Debbie Archer, director of procurement and leader of Vizient’s Innovative Technology program for suppliers. “After a full review of the ivWatch Model 400, Vizient’s member council agreed this solution offers unique and incremental benefits over other products available on the market today, and recommended it for an Innovative Technology contract. We are pleased to award this new contract to ivWatch.”

Vizient, Inc. represents the combined strengths of the organizations formerly known as VHA Inc., University HealthSystem Consortium, Novation and MedAssets’ Spend and Clinical Resource Management. Since 2003, nearly 2200 new and innovative products and technologies have been submitted through the Vizient Innovative Technology program. Vizient works with member-led councils and task forces to identify and review potentially innovative products. If it is determined that a product is innovative, a contract may be awarded outside of Vizient’s competitive bid cycle.

###
MEDIA CONTACT: Leah Moore, leah.moore@ivwatch.com, Office (855) 489-2824 x7031, Mobile (757) 839-5653

ivWatch Wins Top Honors at 2017 Medical Design Excellence Awards


HAMPTON, Va. — June 14, 2017 — ivWatch LLC, a medical device company focused on improving the safety and effectiveness of intravenous (IV) therapy, is pleased to announce it was the Bronze Winner last night in the category of Nonsurgical Hospital Supplies and Equipment at the 2017 Medical Design Excellence Awards (MDEAs), the premier awards program for the medtech industry. The award was presented by Medical Device and Diagnostics Industry magazine at the Jacob K. Javits Center in New York during MD&M East, the largest annual medical technology conference on the East Coast for the medical manufacturing industry.

“It’s an honor for ivWatch to be recognized by the MDEA judges for the outstanding design of our device,” said Gary P. Warren, ivWatch president and CEO. “IV infiltration is a major problem for the medical community as it can lead to serious medical complications and even amputation. Our team of employees, partners and suppliers are committed to solving this problem, and have worked tirelessly to make a significant impact in minimizing patient harm from infiltrations.”

The ivWatch Model 400 continuously monitors a patient’s peripheral IV for evidence of infiltrations, which occur when medication or fluid leaks into the surrounding tissue. Intravenous therapy is a routine part of treatment for nearly 80 percent of patients in the U.S., yet more than 20 percent of these IVs may fail because of infiltration, risking both a serious drug delivery error and tissue damage. Earlier detection of those failures, via ivWatch sensor technology, is the new and next step in minimizing this potential for injury.

MDEA is the medtech industry’s premier manufacturing design competition, recognizing the highest caliber of commercially available products approved by the FDA or other regulating bodies. These awards celebrate the achievements of medical device manufacturers, their suppliers, and the teams behind the scenes who provide input and dedication to innovative products, further improving patient safety across healthcare today.

About ivWatch
ivWatch LLC is a medical device manufacturer focused on improving patient safety and the effectiveness of intravenous therapy. With the Model 400, which is similar to continuous monitors available for a patient’s heart, blood oxygen level and pulse, ivWatch provides a first-of-its-kind, FDA-cleared, noninvasive medical device that continuously monitors peripheral IVs for infiltration and extravasation events. The ivWatch Model 400 aims to help eliminate patient harm associated with adverse events and to reduce drug delivery errors. The ivWatch OEM Board integrates ivWatch technology into existing products, enabling OEMs to help healthcare customers deliver a higher level of patient care and to reduce risks related to IV therapy. Follow us on Twitter@ivWatch or Facebook @ivWatchLLC. www.ivWatch.com

MEDIA CONTACT: Leah Moore, leah.moore@ivwatch.com, Office (855) 489-2824 x7031, Mobile (757) 839-5653

The ivWatch OEM Board is not an FDA-cleared device. It is the responsibility of the Original Equipment Manufacturer integrating ivWatch technology to secure the proper regulatory clearance.

ivWatch Logo White

Download Our Whitepaper

Thank you for requesting more information about the ivWatch Clinical Studies. The ivWatch Model 400 is the only continuous monitoring device for the early detection of IV infiltration and extravasation events.

[fc id='6'][/fc]

You have Successfully Subscribed!

Pin It on Pinterest